Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
The University of Texas at Arlington
Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.
Description
Chronic Kidney Disease (CKD) is a major health problem affecting more than 26 million Americans. Notably, more patients with CKD die of cardiovascular complications than progress to dialysis. An overactive sympathetic nervous system is a well known cardiovascular risk factor present in CKD. The increase in sympathetic nerve activity (SNA) may not only contribute to hypertension, but also accelerates the progression of end organ damage that is independent of any rise in blood pressure. Indeed, elevated SNA is associated with poor prognosis and increased risk of cardiovascular morbidity and mort…
Eligibility
- Age range
- 35–70 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race. * Men and women 35 to 70 years of age Exclusion Criteria: * Allergy to Glitazones * Myocardial infarction * Heart failure * Angina * History of kidney stones * Liver disease (abnormal liver enzymes) * Anemia (hemoglobin \<8 g/dl) * Cancer with current treatment * Previous organ transplan…
Interventions
- DrugPioglitazone
Pioglitazone 15mg daily for 1 month
- OtherPlacebo
Placebo pills for 1 month
Locations (2)
- University of Texas at ArlingtonArlington, Texas
- UT SouthwesternDallas, Texas